ClinicalTrials.gg
Enrolling by invitationNCT05481827ORACLEUpdated Sep 28, 2026

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

A Phase 2 interventional study of GT005 in Age Related Macular Degeneration (AMD), sponsored by Gyroscope Therapeutics Limited. Enrolling by invitation at 32 sites in 6 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Primary conditionGeographic AtrophyRegistry: Macular DegenerationReclassifiedWhy we changed it
Registry
Macular Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Geographic Atrophy
Why
  1. The study's title name Geographic Atrophy, a narrower term within Macular Degeneration.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Gyroscope Therapeutics Limited · Phase 2, Interventional, and Other

Updated Sep 28, 20263 sites added3 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
225
Allocation
Not applicable
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Planned enrollment
38th of 107
225 · median 98
Started
2022
with 4 others
Phase 2
43 of 131
11 open now
Primary completion
2028-06
later than 26 of 44 live
Registered
83rd of 131
by date
Lead sponsor
5 of 131
Gyroscope Therapeutics Limited

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 38th largest by planned enrollment of the 107 interventional ones that give a count, is one of 5 that started in 2022, is one of 43 in phase 2, reaches primary completion later than 26 of the 44 other live ones, and was the 83rd registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety of GT005 in participants with Geographic Atrophy (GA) secondary to AMD who have been treated in an antecedent study.

Read the detailed description

This is a prospective, multi-centre, long-term, follow-up study for participants who have previously received GT005 in one of the antecedent clinical studies which were prematurely terminated GT005-01 (FOCUS), GT005-02 (EXPLORE) or GT005-03 (HORIZON). Participants from GT005-01 (FOCUS) study with only 1 last study visit to be conducted (Week 240) will remain in the study to complete their last visit. No investigational product will be administered within this study, and participants will be invited to enter ORACLE upon their completion or termination of the antecedent interventional study (whichever is soonest). This study will consist of up to three study visits prior to Week 96, and up to five study visits thereafter, for an overall period of 5-years post-GT005 administration.

03

Conditions studied

  • Age Related Macular Degeneration (AMD)

Keywords

  • Geographic Atrophy
  • Retinal disease
  • Retinal degeneration
  • Macular atrophy
  • Dry age-related macular degeneration
  • Macular degeneration
  • age-related macular degeneration (ARMD)
  • retina damage
  • dry macular degeneration
  • AMD
04

In context

Geographic Atrophy Reclassified

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

This study's planned enrollment of 225 is above the median of 70 across 141 interventional studies indexed under Geographic Atrophy.

Browse Geographic Atrophy studies →

Lead sponsor

Gyroscope Therapeutics Limited is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Compared within Geographic Atrophy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Able and willing to give written
  2. Received GT005 in an antecedent study, GT005-01 (FOCUS, NCT03846193), GT005-02 (EXPLORE, NCT04437368) and GT005-03 (HORIZON, NCT04566445)
  3. Willing to attend study visits and complete the study procedures.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
225 participants (estimated)

Study arms

  • Experimental
    GT005

    GT005 is a gene therapy for GA and is a recombinant adeno-associated viral serotype 2 (AAV2) vector encoding for human complement factor I. GT005 was administered to all participants in an antecedent study prior to enrollment in ORACLE and GT005 is not administered in the ORACLE study

    Genetic: GT005

Interventions

  • GeneticGT005

    GT005 is a gene therapy for GA and is a recombinant adeno-associated viral serotype 2 (AAV2) vector encoding for human complement factor I. GT005 was administered to all participants in an antecedent study prior to enrollment in ORACLE and GT005 is not administered in the ORACLE study.

07

What researchers measure

Primary outcomes

  1. Incidence and severity of ocular and systemic adverse events (AEs)

    An AE is the development of an undesirable medical condition or the deterioration of a preexisting medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the IMP.

    Time frame: up to Week 260

08

Study locations

32 sites
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Jun 2028, 70 months after the start.

Of 24 phase 2 interventional studies under Geographic Atrophy, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 54. This study's planned 70 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2022
First posted
Aug 1, 2022
StartActual
Jul 12, 2022
Primary completionEst.
Jun 2, 2028
CompletionEst.
Jun 2, 2028
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 3 sites removed
Show 3 added (2 Germany, 1 United States)
  • Retina Vitreous Associates of Florida · St. Petersburg, United States
  • Universitaetsklinikum Schleswig-Holstein · Lübeck, Germany
  • Universitaetsklinikum Tuebingen · Tübingen, Germany
Show 3 removed
  • Retina Vitreous Associates of Florida · Saint Petersburg, United States
  • Universitaetsklinikum Schleswig-Holstein · Luebeck, Germany
  • Universitaetsklinikum Tuebingen · Tuebingen, Germany
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    3 sites added, 3 sites removed
    Show 3 added (2 Germany, 1 United States)
    • Retina Vitreous Associates of Florida · St. Petersburg, United States
    • Universitaetsklinikum Schleswig-Holstein · Lübeck, Germany
    • Universitaetsklinikum Tuebingen · Tübingen, Germany
    Show 3 removed
    • Retina Vitreous Associates of Florida · Saint Petersburg, United States
    • Universitaetsklinikum Schleswig-Holstein · Luebeck, Germany
    • Universitaetsklinikum Tuebingen · Tuebingen, Germany
    + 3 other changes: verification date, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05481827
Lead sponsor
Gyroscope Therapeutics Limited
Responsible party
Sponsor
First posted
Aug 1, 2022
Start date
Jul 12, 2022
Primary completion
Jun 2, 2028 (estimated)
Completion
Jun 2, 2028 (estimated)
Last update
Sep 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion